Solupharm Limited

Pre-clinical MS Research using EAE models

Solupharm Profile

Figure 1: EAE pathogenesis involves NMDA receptor activation (click image to enlarge)
Dr Bolton has held Lectureship, Fellowship and Honorary appointments at several leading UK universities and was employed as a Senior Scientist, with drug discovery and managerial responsibilities, in the pharmaceutical industry.
 
Dr Bolton played a major role in establishing the use of immunosuppressants, such as Cyclosporin A, in the treatment of autoimmunity and was closely involved in the pre-clinical development of the immunomodulator, Leflunomide. His studies have provided new insights on the therapy of EAE and were the first to confirm a central role for the N-methyl-D-aspartate receptor in neurovascular disruption and demyelination during the pathogenesis of the disease.

Figure 2: EAE-induced blood-brain barrier disruption (click image to enlarge)
 

Figure 3: Suppression of EAE-induced neurovascular damage by memantine (click image to enlarge)
Since the formation of Solupharm Dr Bolton has worked with many national and international pharmaceutical companies to design and implement drug evaluation programmes and assess compound efficacy in models of EAE. He holds Associate Editor and Section Editor appointments, is a Reviewer for several journals and has Expert Witness experience.